For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Xeris Biopharma Holdings Inc (NASDAQ: XERS) was $4.48 for the day, up 4.19% from the previous closing price of $4.30. In other words, the price has increased by $4.19 from its previous closing price. On the day, 2.33 million shares were traded.
Ratios:
Our analysis of XERS’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.19 and its Current Ratio is at 1.67.
On March 28, 2024, Oppenheimer started tracking the stock assigning a Outperform rating and target price of $5.
On August 28, 2023, Craig Hallum started tracking the stock assigning a Buy rating and target price of $4.50.Craig Hallum initiated its Buy rating on August 28, 2023, with a $4.50 target price.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 20 ’25 when Hecht Beth sold 40,000 shares for $5.43 per share. The transaction valued at 217,244 led to the insider holds 1,353,510 shares of the business.
Hecht Beth bought 40,000 shares of XERS for $205,600 on Mar 20 ’25. On Aug 12 ’24, another insider, Schmid John P., who serves as the Director of the company, bought 4,515 shares for $2.25 each. As a result, the insider paid 10,147 and bolstered with 25,200 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 3.40.
Stock Price History:
Over the past 52 weeks, XERS has reached a high of $6.07, while it has fallen to a 52-week low of $1.72. The 50-Day Moving Average of the stock is -2.23%, while the 200-Day Moving Average is calculated to be 28.98%.
Shares Statistics:
A total of 149.43M shares are outstanding, with a floating share count of 141.94M. Insiders hold about 7.80% of the company’s shares, while institutions hold 41.23% stake in the company.
